Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Trial Parameters
Brief Summary
This study evaluates an individualized approach combining highly active maintenance treatment with elranatamab with peripheral blood-based clonotypic measurable residual disease (MRD) testing in patients with newly diagnosed multiple myeloma. The overall goal is to generate efficacy data for a personalized maintenance approach using bone marrow-based MRD testing (clonoSEQ) to guide post-autologous hematopoietic cell transplant (AHCT) maintenance with elranatamab for this patient population.
Eligibility Criteria
Criteria for Pre-Screening Blood Draw * Newly diagnosed multiple myeloma (either untreated or receiving first line therapy). * Potentially eligible for autologous hematopoietic cell transplant (with or without tandem transplant) for frontline therapy. Inclusion Criteria: * At least 18 years of age * Ability to understand and willingness to sign an IRB approved written informed consent document. (Legally authorized representatives may sign and give informed consent on behalf of study participants.) * Received autologous hematopoietic cell transplantation (with or without tandem transplant) as part of frontline therapy for newly diagnosed IgG or IgA multiple myeloma. Frontline therapy in this setting is defined as treatment received prior to first relapse and may include multiple lines of therapy per the Rajkumar et al definition if treatment changes were made for either toxicity or inadequate response to initial induction. * Received frontline treatment with at least a triplet regimen i